Efficacy of Escitalopram in the Treatment of Internet Addiction

Overview

The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

Many individuals experience marked distress and functional impairments as a result of their perceived inability to control their 'non-essential' (non-job/school related) use of the Internet. Frequently these people develop a preoccupation with the Internet, a need for escape to the Internet, and increasing irritability when trying to cut back use of the Internet. There have been no studies to date looking at the effectiveness of medications in the treatment of this disorder. In our clinical experience, we find these patients with Internet addiction usually respond to serotonin reuptake inhibitors within 12 weeks. This study will examine the efficacy of escitalopram in Internet addiction among adults.

Interventions

  • Drug: Escitalopram
    • 10 mg/day

Arms, Groups and Cohorts

  • Experimental: Single Arm
    • Escitalopram

Clinical Trial Outcome Measures

Primary Measures

  • length of non-essential Internet use in hours/week as well as CGI-Improvement
    • Time Frame: baseline and biweekly for 10 weeks

Secondary Measures

  • ratings on depression, anxiety, impulsivity, self-esteem, obsessive-compulsive symptoms
    • Time Frame: baseline and biweekly for 10 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Subject has signed an informed consent form 2. Current diagnosis of Internet addiction 3. Age ³ 18 4. Subject must be able to take oral medication 5. Subject may be in psychotherapy initiated at least three months prior to Screening. Subject must not discontinue or otherwise alter this therapy during the study. 6. In the opinion of the investigator, the subject is capable of complying with all study procedures. Exclusion Criteria:

1. Current suicidal or homicidal ideation 2. Subject has a primary diagnosis of schizophrenia or other psychotic disorders 3. Subject has a primary diagnosis of Bipolar I disorder 4. Current pedophilia 5. Current DSM-IV diagnosis of substance dependence or abuse, excluding nicotine 6. Women of child-bearing potential who are pregnant, nursing, or not using contraception 7. Use of antidepressants at a therapeutic level for the treatment of problematic internet use within 2 weeks prior to study entry (or 4 weeks for use of MAOIs, or 6 weeks for use of fluoxetine) 8. Current use of antidepressants at a therapeutic level for the treatment of a disorder other than problematic internet use 9. Subject has any organic mental disorder 10. Clinically significant unstable medical disorder

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Icahn School of Medicine at Mount Sinai
  • Collaborator
    • Forest Laboratories
  • Provider of Information About this Clinical Study
    • Dr. Eric Hollander, Mount Sinai School of Medicine
  • Overall Official(s)
    • Eric Hollander, MD, Principal Investigator, Icahn School of Medicine at Mount Sinai

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.